



## **Kuros Biosciences Proposes Election of Four New Board Members**

**Schlieren (Zurich), Switzerland, April 28, 2017 – Kuros Biosciences Ltd (“Kuros”) today announced that the Board of Directors (“Board”) proposes to the upcoming General Meeting the election of Professor Clemens van Blitterswijk, Frank-Jan van der Velden, Giacomo Di Nepi and Dr. Ivan Cohen-Tanugi as new members of the Board. The General Meeting will take place in Schlieren on May 22, 2017.**

“Kuros is in transition to become a commercial-stage orthobiologics company. Ahead of the pending market launches of our product lines, we look to strengthen the commercial and scientific expertise on the Board. We are delighted to propose to our shareholders four distinguished experts in their respective fields for the election as new members of the Board”, comments Dr. Christian Itin, Chairman of the Board of Directors.

### **Biographical information on the proposed new Board members**

**Dr. Ivan Cohen-Tanugi** has been named Chief Executive Officer in April 2017. He joined the Company with more than 20 years of experience in leadership roles in the life sciences industry. Dr. Cohen-Tanugi held various managing positions at Sanofi, Roche, Amgen, Teva, Eyevensys and Stallergenes-Greer including as Head of Amgen Europe Nephrology, General Manager Teva North America Biologics & Specialty and CEO of Eyevensys. He received his medical degree at Grenoble School of Medicine, France, and obtained a MBA at H.E.C. Business School, Paris, France. Dr. Cohen-Tanugi is French and US citizen.

**Giacomo Di Nepi** brings over 30 years’ experience in the industry. Currently, he is CEO of Polyphor Ltd, Allschwil, Switzerland. Before, he was Executive Vice President and General Manager, Europe for InterMune Inc., where he launched Esbriet, an orphan drug, and built from scratch a USD 140 million and 200 people business – until the acquisition of InterMune by Roche for USD 8.3 billion. Previously, Mr. Di Nepi was in senior leadership responsibilities with Takeda and Novartis, where he was member of the Pharma Executive Committee. Prior, he was a Partner with McKinsey. Mr. Di Nepi currently serves on the boards of Geneuro (GNRO.PA) and NTC, a privately held company. He holds a degree in Economics from Bocconi University, Milan, Italy, and an MBA from INSEAD, Fontainebleau, France. Mr. Di Nepi is Italian citizen.

**Professor Clemens van Blitterswijk**, PhD, is the Department Chair and Professor at MERLN Institute for Technology-Inspired Regenerative Medicine at Maastricht University, The Netherlands. Prof van Blitterswijk has founded nine companies over the years. He is recipient of numerous national and international awards like recently “the most entrepreneurial professor of the Netherlands”. He brings over two decades of entrepreneurial science to the Kuros team. Prof van Blitterswijk has authored and co-authored over 350 scientific papers and is inventor on more than 100 patents. He has published three books as an editor, and contributed to many more as a contributing author. Prof van Blitterswijk is a biologist by training and has a PhD in Medicine from Leiden University, The Netherlands. He is Dutch citizen.



**Frank-Jan van der Velden**, MBA, co-founded Xpand Biotechnology (“Xpand”) in 2005, which became a wholly owned subsidiary of Kuros Biosciences in January 2017, and has been a member of Kuros’ Executive Committee since the acquisition. He was co-founder of several other companies in the field of regenerative medicine amongst others CellCoTec, Progentix Orthobiology and Materiomics. Prior to co-founding Xpand, Mr. van der Velden was partner at Krüger & Partners management consultants for ten years after 10 years as director of Quote Media Holding. Currently, he is chairman of the supervisory board of TIIN Techfund III (venture capital fund for technology start-ups), board member of RiverDiagnostics International (a manufacturer of Raman spectroscopy equipment for life science application) and member of the executive committee of Materiomics (high-throughput screening for cell-surface topography interaction). Mr. van der Velden is a graduate of Erasmus University Rotterdam School of Management, The Netherlands. He is a Dutch citizen.

**Full agenda available from Kuros’ website**

The General Meeting 2017 will take place at the Company’s offices in Schlieren/Zurich (Switzerland) on May 22, 2017 at 4.00 pm. The formal invitation to the meeting will be mailed within the next few days and can also be accessed from Kuros’ website at <http://kuros.ch/investors/calendar.html>.

**For further information, please contact:**

Kuros Biosciences Ltd  
Harry Welten, MBA  
Chief Financial Officer  
Tel: +41 44 733 46 46  
[harry.welten@kuros.ch](mailto:harry.welten@kuros.ch)

**About Kuros Biosciences**

*Kuros Biosciences Ltd is a leading, commercial-stage company focused on the development of innovative products for tissue repair and regeneration. The Company’s first product, MagnetOs, is approved for sale in the EU and under regulatory review in the US. In addition, Kuros’ second product, Neuroseal, is under review in the EU. The Company is located in Schlieren (Zurich), Switzerland. Kuros’ shares are listed according to the Main Standard on the SIX Swiss Exchange Ltd under the symbol KURN. Visit [www.kuros.ch](http://www.kuros.ch) for more information.*

**Forward Looking Statements**

*This media release contains certain forward-looking statements that involve risks and uncertainties that could cause actual results to be materially different from historical results or from any future results expressed or implied by such forward-looking statements. You are urged to consider statements that include the words “will” or “expect” or the negative of those words or other similar words to be uncertain and forward-looking. Factors that may cause actual results to differ materially from any future results expressed or implied by any forward-looking statements include scientific, business, economic and financial factors, Against the background of these uncertainties, readers should not rely on forward-looking statements. The Company assumes no responsibility for updating forward-looking statements or adapting them to future events or developments.*